Atypical IκB proteins – nuclear modulators of NF-κB signaling by Marc Schuster et al.
Schuster et al. Cell Communication and Signaling 2013, 11:23
http://www.biosignaling.com/content/11/1/23REVIEW Open AccessAtypical IκB proteins – nuclear modulators of
NF-κB signaling
Marc Schuster1,2, Michaela Annemann1,2, Carlos Plaza-Sirvent1,2 and Ingo Schmitz1,2*Abstract
Nuclear factor κB (NF-κB) controls a multitude of physiological processes such as cell differentiation, cytokine
expression, survival and proliferation. Since NF-κB governs embryogenesis, tissue homeostasis and the functions of
innate and adaptive immune cells it represents one of the most important and versatile signaling networks known.
Its activity is regulated via the inhibitors of NF-κB signaling, the IκB proteins. Classical IκBs, like the prototypical
protein IκBα, sequester NF-κB transcription factors in the cytoplasm by masking of their nuclear localization signals
(NLS). Thus, binding of NF-κB to the DNA is inhibited. The accessibility of the NLS is controlled via the degradation
of IκBα. Phosphorylation of the conserved serine residues 32 and 36 leads to polyubiquitination and subsequent
proteasomal degradation. This process marks the central event of canonical NF-κB activation. Once their NLS is
accessible, NF-κB transcription factors translocate into the nucleus, bind to the DNA and regulate the transcription
of their respective target genes. Several studies described a distinct group of atypical IκB proteins, referred to as the
BCL-3 subfamily. Those atypical IκBs show entirely different sub-cellular localizations, activation kinetics and an
unexpected functional diversity. First of all, their interaction with NF-κB transcription factors takes place in the
nucleus in contrast to classical IκBs, whose binding to NF-κB predominantly occurs in the cytoplasm. Secondly,
atypical IκBs are strongly induced after NF-κB activation, for example by LPS and IL-1β stimulation or triggering of B
cell and T cell antigen receptors, but are not degraded in the first place like their conventional relatives. Finally, the
interaction of atypical IκBs with DNA-associated NF-κB transcription factors can further enhance or diminish their
transcriptional activity. Thus, they do not exclusively act as inhibitors of NF-κB activity. The capacity to modulate NF-κB
transcription either positively or negatively, represents their most important and unique mechanistic difference to
classical IκBs. Several reports revealed the importance of atypical IκB proteins for immune homeostasis and the severe
consequences following their loss of function. This review summarizes insights into the physiological processes
regulated by this protein class and the relevance of atypical IκB functioning.
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NF-κB signaling
NF-κB transcription factors are homo- or hetero dimers
composed of two REL proteins, such as p50 and p65 [1].
This family consists of p65/RelA, p50, p52, RelB and c-Rel.
Their common structural motif is the Rel homology domain
(RHD) [2]. It contains a dimerisation sequence for the inter-
action with other REL proteins, a nuclear localization signal
(NLS) regulating its subcellular localization and a DNA* Correspondence: ingo.schmitz@helmholtz-hzi.de
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reproduction in any medium, provided the orbinding motif for the interaction with κB sites in regulatory
sequences of their respective target genes. Transactivation
domains, TAD, are found in p65/RelA, c-Rel and RelB,
whereby NF-κB dimers containing at least one of these sub-
units can induce transcription [2]. On the other hand, NF-
κB homodimers of p50 and p52 function as transcriptional
repressors due to the lack of such a sequence [2]. They ei-
ther compete for activating NF-κB transcription factors by
occupation of DNA binding sites, or recruit gene-silencing
proteins such as histone deacetylases (HDACs) [3], or inhibit
transcription by use of both mechanisms. Each REL-protein
subunit, with its individual and slightly different DNA-
binding domain, contributes to the total DNA-affinity of thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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quence for NF-κB binding is not identical among the differ-
ent dimer combinations. This results in a magnitude of
optimal regulatory sequences. The diversity of ideal binding
sites, the multitude of κB-sites in the DNA and the existence
of suppressive and inducive NF-κB dimers are the reasons
of the complexity and versatility of the downstream signal-
ing network.
NF-κB can be activated in two different fashions,
called canonical and non-canonical NF-κB activation.
Both pathways use a complex formed by IκB kinase pro-
teins, however, in slightly different compositions [2,7].
Regulation of the upstream signaling events and detailed
differences between the canonical and non-canonical
NF-κB activation were previously illustrated and are not
part of this review [2,7].
Canonical NF-κB activation
The canonical signaling is initiated by a variety of recep-
tors, like members of the TNF receptor super-family,
Toll-like receptors, interleukin receptors and antigen re-
ceptors of B and T cells [2]. Their common downstream
signaling complex is a trimeric IκB kinase complex
consisting of the catalytic subunits IKKα, IKKβ and the
regulatory subunit IKKγ/NEMO [8,9]. The sequestration
of NF-κB in the cytoplasm is mediated by the association
of classical IκBs such as the prototypical protein IκBα to
inhibit NF-κB binding to the DNA [10-13]. The charac-
teristic structural motif of IκB proteins is a repetitive se-
quence of 6 to 10 ankyrin domains [2]. Binding of these
ankyrin repeats to the REL homology domain of NF-κB
results in masking of the NLS [14,15]. Crystallography
demonstrated that the ankyrin domain of IκBα localizes
between the carboxy-terminal Ig-like sequences of the
REL homology domains of two NF-κB subunits [16].
When the NLS is accessible the NF-κB transcription fac-
tor can localize in the nucleus and bind to the DNA,
which depends on IκBα degradation [17,18]. In case of
IκBα this process is initiated by phosphorylation of the
serine residues 32 and 36 by activated IKKβ [18-20]. The
phosphorylated serines within the so-called “destruction
box” of IκBα are subsequently recognized by the E3 lig-
ase βTRCP leading to polyubiquitination and eventually
causing proteasomal degradation of IκBα [17,21-23]. As
the NLS of the NF-κB dimer is accessible the transcrip-
tion factor localizes into the nucleus and modulates
transcription via binding to the DNA.
Non-canonical NF-κB activation
The non-canonical NF-κB activation depends on an
IKKα homodimer, activated for example by triggering of
the BAFF receptor, CD40 or the lymphotoxin-β receptor
[7,24,25]. The NF-κB dimers activated in the non-
canonical signaling cascade are composed of p52 andRelB [26]. Their NLS sequences are masked intra-
molecularly by the precursor protein of p52, p100, which
displays carboxy-terminal ankyrin repeats to interact
with the REL domains and hide the NLS [27]. Phosphor-
ylation of p100 causes cleavage of the protein into p52
leading to the nuclear translocation of NF-κB [26,28]. As
the ankyrin repeats are part of the sequences of p100 as
well as p105, the precursor of p50, the existence of a
common evolutionary ancestor for both, IκB and REL
proteins is reasonable. Alternatively, p100 and p105
could be the result of a gene fusion.
Nuclear modulation of NF-κB activity
NF-κB activity is fine-regulated in the nucleus by a variety
of mechanisms, including post translational modifications
of REL proteins for example sumoylation, phosphoryl-
ation, acetylation and ubiquitination [3,29]. Besides, the
nuclear IκB proteins of the BCL-3 class BCL-3, IκBNS,
IκBζ and IκBη can dramatically alter NF-κB-mediated ef-
fects via the regulation of dimer exchange, the recruitment
of histone modifying enzymes or the stabilization of NF-
κB dimers on the DNA. Although, these proteins formally
belong to the IκBs due to the presence of ankyrin repeats
in their structure (Figure 1), they do not functionally act
exclusively as repressors of NF-κB-mediated transcription,
but more as NF-κB modulators (Table 1).
BCL-3
Initial description and structure
BCL-3 was the first identified atypical IκB protein. It con-
sists of an amino-terminal TAD followed by 7 Ankyrin re-
peats and a second carboxy terminal TAD, displaying an
overall length of 448 amino acids (Figure 1). It was first
described as a proto-oncogene expressed in patients,
which suffered from B-cell chronic lymphocytic leukemia
displaying the translocation t (14:19)(q32;q13.1) [30].
Function
The oncogenic potential of BCL-3 is illustrated by its
capacity to dampen the tumor suppressor p53 and to
force Cyclin D1 expression in order to enhance prolifer-
ation [31,32]. As the protein is expressed by a variety of
different non-Hodgkin and Hodgkin lymphomas it could
represent a suitable pharmacological target for the treat-
ment of cancer [33,34]. Electrophoretic mobility shift as-
says initially revealed that the protein interacts with p50
and p52 and can inhibit DNA binding [32,35]. In con-
trast to IκBα, which sequesters p50 in the cytoplasm,
BCL-3 is localized in the nucleus and alters the sub-
nuclear localization of p50. In COS cells p50 was rela-
tively equally distributed when overexpressed alone,
however cotransfection with BCL-3 resulted in its accu-
mulation in nuclear spots [36]. From these analyses it
was thought that BCL-3 might act as an anti-repressor
Figure 1 Alignment of atypical IκB proteins. Alignment of murine atypical IκB proteins IκBζ long, IκBζD, IκBζ short, IκBNS, IκBη and BCL-3 is
shown. Position of ankyrin repeats (grey), transactivation domains, TAD, and nuclear localization signal (orange) are indicated within the coding
sequence (yellow). Identity between the sequences is indicated in the upper part of the diagram with green showing highest similarity and red
lowest similarity. Sequences NP_001152867, NP_082941, NP_085115, NP_291079 and NP_742154 were used for the alignment created by
Geneious v5.3 software (Drummond et al., 2010; available at www.geneious.com/).
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promoters of its target genes, which allows binding of
activating p50/p65 or comparable heterodimers and in-
directly forces transcriptional activation. Transcriptional
repression of BCL-3 is also directly regulated via its
binding to HDAC-1, -3 and -6 [37]. In macrophages,
LPS is a potent inducer of BCL-3 [38,39], which inter-
acts with p50 to reduce NF-κB-mediated TNF-α produc-
tion. In agreement with the formation of nuclear
suppressor complexes, it was suggested that this effect is
mediated via chromatin remodeling. This is based on
the fact that HDAC-1 overexpression further enhanced
BCL-3-mediated suppression and trichostatin A treatment
abrogated the BCL-3-mediated effects [39]. Alternatively,
BCL-3 can suppress transcription via block of the
ubiquitination of p50 to stabilize a suppressive NF-κB com-
plex within the nucleus [38]. Thus, BCL-3-deficient macro-
phages display enhanced expression of pro-inflammatory
cytokines upon LPS treatment, as degradation of inhibitory
p50 homodimers is not blocked. Surprisingly, an early study
reported that BCL-3 had the potential to induce transcrip-
tion directly via an amino terminal proline rich region and a
second carboxy-terminal serine/proline rich region [40]. It
was later shown that its carboxy-terminal tail enhances tran-
scription via interaction with c-Jun, c-Fos, CREB-binding
protein/p300 and the steroid receptor coactivator-1 (SRC-1),
with CBP/p300 and SRC-1 having acetyltransferase activity
[41]. Remarkably, both the amino and carboxy terminalsequences are needed for the full transcriptional activity of
BCL-3, suggesting, that both sequences function coopera-
tively [40]. An additional part of the nuclear BCL-3 complex
is the BCL-3 binding protein B3BP thought to be involved
in DNA repair, which forms a complex with p300 and
BCL-3 [42]. In addition to p300, the acetyltransferase Tip60
is another interaction partner of BCL-3/p50 complexes,
which can enhance transcriptional activity [43]. A recent re-
port nicely demonstrated that p52/BCL-3 complexes bind
to A/T and G/C centric NF-κB binding sites sequences,
however, with a dramatically altered transcriptional outcome
[44]. Via G/C centric elements these complexes induce tran-
scription throughTip60 recruitment, but suppress via bind-
ing to A/T centric elements and recruitment of HDAC3.
BCL-3 itself is critically regulated via post-translational
modifications, especially via phosphorylation and ubiqui-
tination. It was shown that phosphorylation of BCL-3 via
GSK3 regulated BCL-3 degradation and oncogenicity
[37,45]. However, its proteasomal degradation in the cyto-
plasm is regulated by an E3-ligase complex containing
TBLR1, which appears to be independently of GSK3 [46].
In all known pathways, NF-κB activity is regulated by sev-
eral upstream ubiquitination events through the bal-
ance between ubiquitin ligases and deubiquitinases
[2,47]. CYLD, a K63-deubiquitinase inhibits NF-κB ac-
tivation in TRAF2-mediated NF-κB signaling pathways
[48]. Remarkably, BCL-3 also becomes deubiquitinated
by CYLD in the nucleus, upon UV-irradiation. This
Table 1 Properties of atypical IκB proteins
BCL-3 IκBζ IκBNS IκBη IκBL
Alternative names B-cell CLL/lymphoma 3 , D19S37,
AI528691
Nfkbiz, FLJ30225, FLJ34463, INAP, MAIL,
AA408868
Nfkbid, IkB-delta, MGC11314, MGC149503,










Human: Human: Human: Human: Human:
19q13.1-q13.2 3p12-q12 19q13.12 11q14.1 6p21.3
(602) (64332) (84807) (338699) (4795)
Mouse: Mouse: Mouse: Mouse: Mouse:
7A3; 7 9.95 cM 16; 16 C1.2-C1.3 7 B1; 7 7; 7E2 17 B1; 17
(12051) (80859) (243910) (73845) 18.6 cM (18038)
Interaction
partners
p50 [35,36,40], p52 [32], c-Jun [41],
c-Fos [41], CREB/p300 [41,43], SRC-1
[41], B3BP [42], Tip60 [43],
HDAC-1/-3/-6 [37,45]
p50 [64], STAT3 [71], FUSS-DDIT3 [72],
p65 [73], RORγ [77], RORα [77]





Bone marrow, spleen, lymph nodes,
peritoneal lavage, kidney, liver [52]
Heart, skeletal muscle, spleen, kidney,
liver, placenta, lung, peripheral blood,
leukocytes [73]






Reduction of Peyer’s Patches [53].
Lack of splenic marginal centers [51].
Dermatitis-like skin irritations [74].
Ocular surface inflammation [76].
Resistant to EAE [77].
Less Treg cells [80]. Unknown Unknown
Induced via LPS [39], IL-9 [54], IL-4 [57] LPS [61], IL-1 [64], BLP [64], PGN [64],
MALP [64], Flagellin [64], peptidoglycan [67],
β-glucan [67], CpG-DNA [67], IL-18 [70],
IL-12 [70]
LPS [79,82], CD3 [80], anti-IgM [83],
CD40 [83]
LPS [87], poly(I:C) [87], CpG-





IP-10 [44], IL-10 [44], MCP-1 [44],
CD95 [44], CD40 [44], IL-23p19 [44],
CyclinD1 [32], TNFα [39], Gata3 [55]
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its inactivation [48].
Transgenic mouse models
BCL-3 function was examined using a variety of different
transgenic mouse models. Eμ-BCL-3 transgenic mice display
splenomegaly, lymphadenopathy and elevated levels of ma-
ture B cells in the secondary lymphoid organs, the peritoneal
cavity and the bone marrow, suggesting that BCL-3
overexpression renders B cells into a state of hyperactivation
[49]. In agreement with this observation, BCL-3-deficient
mice display a variety of defects in their humoral immune
response. They lack germinal centers in the spleen and show
impaired clearance of Listeria, Streptococci and Toxoplasma
infections since they cannot mount a pathogen-specific
antibody response [50-52]. Upon Listeria infection, re-
duced IL-12p70 and IFNγ levels were detected, which
is presumably the result of increased levels of anti-
inflammatory IL-10 produced by macrophages [50]. In
addition, like p50-deficient mice, BCL-3-deficient mice
display reduced Peyer´s Patches but not a complete ab-
sence of them as seen in p52/p100-deficient mice [53].
Besides the role of BCL-3 in B cells, the protein has
several properties important for T cells survival and
differentiation. In T cells and mast cells, BCL-3 is
upregulated by IL-9 and IL-4 via the Jak/STAT path-
way [54]. When BCL-3 is absent, induction of GATA-3
by IL-4 is dramatically impaired and, thus, TH2 devel-
opment [55]. In contrast to this, the generation of
IFNγ-producing TH1 cells is not altered in BCL-3
compromised mice [55,56]. However, the protein en-
hances IFNγ expression in CD8 cells upon second
antigen exposure [56]. In addition, IL-4 protects cells
from apoptosis via BCL-3. One report demonstrated
that BCL-3 expression is lost upon IL-4 deprivation,
leading to apoptosis [57]. In agreement, ectopic
overexpression of BCL-3 effectively protected cells
from IL-4 deprivation-induced death [57]. Consequently, it
was suggested that BCL-3 could have anti-apoptotic poten-
tial. Indeed, another report demonstrated that BCL-3-defi-
cient T cells are highly sensitive towards activation-induced
cell death due to over-activated pro-apoptotic Bim [58]. In
line, transgenic overexpression of BCL-3 prolonged T cell
survival. In the context of T cells it was further shown, that
BCL-3 in cooperation with p52 is important in regulating
central tolerance [59]. However, this effect is not intrinsically
mediated by T cells, but controlled by medullary thymic epi-
thelial cells, which are required for selection of Tcells. These
cells display impaired maturation in BCL-3/p100 double-
deficient mice, leading to severe autoimmunity [59]. In
terms of autoimmune diseases it should be noted, that
BCL-3 is also a suppressor of autoimmune diabetes, as
BCL-3-deficient NOD mice are more susceptible to auto-
immune diabetes and display higher levels of IL-17 [60].Conclusive remarks
The protooncogene BCL-3 displays remarkable versatility
in the regulation of NF-κB, for example via NF-κB
stabilization in the nucleus or removal of the transription
factor from the DNA. Via the recruitment of HAT and
HDAC proteins BCL-3 can mediate opposing effects on
transcription.
IκBζ
Initial description and structure
IκBζ was first identified by a differential display analysis
in a variety of tissues upon i.p. injection of LPS in
wildtype mice [61]. It was initially termed “molecule
possessing ankyrin repeats induced by LPS” (MAIL),
which is still a frequently used name for its murine
isoforms [61]. A second study found IκBζ upon IL-1β
treatment of OP9 stroma cells leading to its alternative
name “interleukin-1 inducible nuclear ankyrin-repeat
protein” (INAP) [62]. Up to now, its most common
name is IκBζ for both the human and murine proteins
[63]. IκBζ consists of a NLS (amino acids 163–178), a
transactivation domain (amino acids 329–429), and
seven ankyrin repeats (amino acids 450–700) (Figure 1).
Early studies demonstrated the nuclear localization of
IκBζ in 3T3 and OP9 cells, strong sequence homology of
its Ankyrin-repeat containing C-terminal tail to BCL-3
and interaction with p50/p50 homodimers [61,62,64,65].
So far, three murine isoforms of the protein were de-
scribed. Initially reported were MAILL (728 amino acids)
and the N-terminal truncated isoform MAILS (629
amino acids) (Figure 1) [61]. Of these two isoforms, the
long protein seems to be more prominently expressed
[66]. The third isoform, IκBζ-D, is a splicing variant lack-
ing amino acids 236–429 [65]. This deletion results in
loss of the suggested transactivation domain (Figure 1).
Consequently, IκBζ-D fails to augment NF-κB activity in
contrast to the full length protein [65].
Function
IκBζ/p50/p50 complexes bind to the IL-6 locus and potenti-
ate transcription in macrophages upon TLR-2, -4 and -9
and IL-1R triggering [64,67]. In agreement, overexpression
of the downstream signaling mediators MyD88 and TRAF6
can induce IκBζmRNA [67]. IκBζ-deficiency causes a reduc-
tion of IL-6 and of IL-12p40 expression [64], whereas its
overexpression enhances IL-6 production [61]. In contrast
to those two cytokines, TNFα transcription is suppressed by
IκBζ, which nicely illustrates its dual functionality [65]. So
far, several stimuli are known, which force the expression of
IκBζ. In addition to the early identified triggers of IκBζ in-
duction, LPS and IL-1β [67], stimulation of macrophages
with peptidoglycan, β-glucan and CpG-DNA can also in-
duce IκBζ expression [67]. On the other hand, its mRNA is
not detectable upon TNFα or PMA treatment of OP9 cells
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(encoding for IκBζ) upon TNFα treatment is not markedly
different compared to stimulation with IL-1β or LPS [68].
IκBζ mRNA is not detectable upon TNFα treatment alone,
because it requires stabilization via IL-1β, LPS or IL-17 [68].
TNFα and IL-17 treatment in combination, however, is suf-
ficient to induce IκBζ. Analyses of the murine IκBζ locus
also revealed the presence of κB binding sites in its pro-
moter, which suggests its regulation by NF-κB [69]. In agree-
ment with this report, overexpression of dominant negative
IκBα can prevent the induction of IκBζ by LPS treatment
[67]. Interestingly, ectopic overexpression of the upstream
kinases NIK and IKKβ was also sufficient to cause IκBζ-
induction in contrast to overexpression of the downstream
protein p65 [67].
A recent investigation addressed the function of IκBζ
in NK cells. It was shown that IκBζ is induced and
recruited to proximal promoter regions of the ifng gene
upon IL-12 or IL-18 stimulation [70]. As a result of im-
paired NK cell activation IκBζ-deficient mice were more
susceptible to MCMV infections. The effect could be
pinpointed to impaired binding of STAT4 to the ifng
locus. Remarkably, in IκBζ-deficient NK cells STAT4
phosphorylation remained unaffected [70]. Next to the
regulation of STAT4, IκBζ was also reported to interact
directly with STAT3 via its coiled-coiled domain [71].
Binding of IκBζ results in a dramatic reduction of the
transcriptional activity of STAT3. Thereby, transcription
of an anti-apoptotic target gene of STAT3, MCL-1, is
impaired leading to enhanced apoptosis [71]. Another
study revealed its co-localization and interaction with
the nuclear fusion oncoprotein FUSS-DDIT3, originating
from t(12;16)(q13;p11), which forces the development of
myxoid liposarcomas [72]. It was shown that this com-
plex binds to the IL8 locus and thereby enhances its ex-
pression [72]. The modulation of chromatin remodeling
through IκBζ was also suggested by the observation that
the human protein co-localizes with HDAC-4 and
HDAC-5 in nuclear spots [73]. In contrast to the murine
protein, human IκBζ presumably interacts with p65 and
suppresses its transcriptional activity through HDAC re-
cruitment [73]. However, interaction studies and reporter
assays were performed using ectopically overexpressed
proteins in HEK 293 cells. As a consequence it still re-
mains uncertain whether murine and human IκBζ show
differences regarding the interaction with Rel proteins. It
was further shown that the human protein is inducible by
IL-1β and TNFα in MCF-7 and Hela cancer cells [73]. In
contrast, stimulation of murine macrophages with TNFα
alone was not sufficient to induce IκBζ mRNA [62,64,68],
indicating that either tumor development alters IκBζ regu-
lation or that the murine and human proteins are regu-
lated in a different fashion. In addition, RNAi-mediated
knockdown of IκBζ rendered Hela cells more resistanttowards TNFα and CD95-mediated apoptosis [73]. Al-
though certain data indicate differences in the regulation
and interaction of murine and human IκBζ, further inves-
tigations need to be done to verify functional differences
between the proteins of the two species.
Transgenic mouse models
IκBζ-deficient mice develop several signs of autoimmune
syndromes. These comprise severe skin irritations in the
face, neck and periocular regions appearing between
weeks 4 and 8 after birth [74]. Further analyses revealed
constitutive expression of IκBζ in keratinocytes [75]. Re-
markably, its expression was not altered upon LPS treat-
ment in vivo or in vitro, in contrast to IL-1β treatment,
which enhanced IκBζ transcription. This indicates the
specific repression of LPS-induced IκBζ expression in
keratinocytes. Thus, IκBζ appears to be a mediator of
skin homeostasis, whereby its deficiency causes a
dermatitis-like phenotype. Remarkably, IκBζ is expressed
in a variety of mucosal tissues, such as the ocular surface
epithelium [76]. Its deficiency causes chronic inflamma-
tion of the ocular surface, leading to infiltration of B220+
and CD4+ cells in the submucosa. This proposes a role
as negative regulator of pathologic progression of ocular
surface inflammations [76]. The importance of IκBζ for
adaptive immune cells was impressively demonstrated
for TH17 cells. IκBζ binds, together with RORγ or
RORα, to the IL-17a locus [77]. Their combined
overexpression could enhance TH17 development from
naïve T cells, even without TGFβ and IL-6 treatment.
Moreover, IκBζ deficiency impairs TH17 development
and results in complete resistance to experimental in-
duced autoimmune encephalomyelitis (EAE) [77]. Thus,
IκBζ could be a pharmaceutical target for the treatment
of multiple sclerosis (MS).
Conclusive remarks
In summary, IκBζ can be considered a pro-inflammatory
IκB protein, as it is necessary for the generation of
TH17 cells and the production of IL-6 upon LPS expos-
ure. However, as constitutive protein expression in
keratinocytes prevent immune cell infiltration in the skin
and IκBζ-deficient mice display signs of dermatitis, loss
of the protein can also cause inflammatory syndromes.
IκBNS
Initial description and structure
IκBNS, also known as TA-NFKBH and Nfkbid, consists
of 327 amino acids and, therefore, is the smallest
member of the BCL-3 subfamily [78]. IκBNS was ini-
tially identified by RDA analysis, investigating genes in-
duced upon negative selection of T cells in the thymus
[78]. It consists almost entirely of six ankyrin repeats and
short C- and N-terminal tails, but no transactivation
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IκBNS with other NF-κB family members is not entirely
clear. It was shown that overexpressed IκBNS predomin-
antly interacts with p50 but not p65 in RAW264.7 macro-
phages [79]. However, pulldown experiments using GST-
IκBNS and protein extracts from stimulated N15 TCR
transgenic thymocytes demonstrated binding to cytoplas-
mic and nuclear p50 as well as nuclear p52, p65, RelB and
c-Rel [78]. Therefore, it is conceivable that IκBNS can
interact with several different NF-κB dimers in the nu-
cleus. One study reported mild interaction of endogenous
IκBNS and c-Rel in stimulated T cells [80]. The presence of
a specific interaction might depend on posttranslational
modifications and on the analyzed cell type.
Transgenic mouse models and function
The generation of IκBNS-deficient mice revealed that the
protein is dispensable for negative selection, since CD4
and CD8 T cell numbers and Vβ expression are identical
between IκBNS-deficient and wildtype mice [81]. More-
over, analyses of TCR specificities indicated unaltered re-
activity to antigens compared to wildtype mice. However,
it was shown that IκBNS is inducible in mature CD4 Tcells
upon TCR stimulation [80]. Its deficiency causes reduced
expression of IL-2 and IFNγ upon stimulation by anti-
CD3 and anti-CD28 and mildly impaired proliferation,
which could be overcome by treatment with PMA and
ionomycin [81]. In IκBNS-deficient macrophages and DCs,
however, LPS triggering resulted in prolonged and en-
hanced expression of IL-6 and IL-12p40 [79,82]. To this
end it is thought that a complex containing p50 and IκBNS
is required to terminate IL-6 expression. The reductions
of IL-6 and IL-12p40 on the one hand and the inductions
of IL-2 and IFNγ on the other hand underline the dual
function of atypical IκB proteins as repressors or inducers
of transcription also for IκBNS. It is also interesting, that
IκBNS acts antagonistic to IκBζ in the regulation of IL-6 in
macrophages [64,79]. Next to macrophages and T cells, a
recent report suggested a role for IκBNS in B cell develop-
ment, as it is induced by LPS, anti-IgM and CD40 trigger-
ing [83]. Notably, IκBNS-deficient mice lack the entire B1
B cell compartment and display reduced B cell numbers
in the marginal zone [83,84]. Corresponding to impaired
T cell proliferation upon TCR triggering, proliferation was
reduced upon LPS and anti-CD40 triggering in IκBNS-
deficient B cells [83]. In agreement with the impaired
generation of plasma cells in vitro, serum IgM and
IgG3 levels were dramatically reduced and less
antigen-specific antibodies were produced upon influ-
enza infection of IκBNS-deficient mice. Remarkably,
one report demonstrated, that IκBNS expression is
suppressed by an AP-1/Foxp3 complex [85]. Foxp3
governs the generation and function of immunosup-
pressive regulatory T cells. Of note, IL-2 secretion inTreg cells is prevented. Thus, it is conceivable that
IκBNS repression might ensure silencing of IL-2 tran-
scription in Treg cells, as it is needed for IL-2 induc-
tion upon activation of CD4 and CD8 cells [81].
Although the protein is repressed in Foxp3+ Tregs,
IκBNS is important for the maturation of Foxp3
- Treg
precursors [80]. Thus, Treg cells are reduced in IκBNS-
deficient mice. Whether or not human IκBNS functions
in a similar fashion remains unknown. The sole report
on human IκBNS demonstrated that its mRNA is in-
duced upon IL-1β treatment of immortalized human
gingival fibroblasts, along with the other NF-κB pro-
teins p50, p52, p65, RelB IκBα, IκBε, and IκBζ [86].
Conclusive remarks
IκBNS is necessary for the generation of immunosuppres-
sive Treg cells and the termination of pro-inflammatory
cytokines like IL-6 and IL12p40. On the other hand it pro-
motes germinal center reactions and IL-2 induction. Thus,
the protein mediates immune activation as well as sup-
pression. Therefore, it is an important regulator of im-
mune homeostasis, although it cannot simply be classified
as a pro- nor anti-inflammatory signaling protein.
IκBη
IκBη is the most recently identified member of the BCL-3
subfamily, found by microarray analyses of bone marrow
derived DCs [87]. It was shown that the protein made up
of 516 amino acids is induced upon LPS, polyI:C, CpG
DNA and zymosan treatment in RAW264.7 macrophages
[87]. In contrast to the other BCL-3 proteins, it consists of
8 ankyrin domains and a prolonged carboxy terminal tail
(Figure 1). Co-Immunoprecipitation experiments demon-
strated its interaction with p50, but not with p65. Its
siRNA-mediated knockdown led to the loss of the expres-
sion of several pro-inflammatory genes, such as the clas-
sical NF-κB target genes Il6, Il1b and ifnb [87]. In
agreement with the reduced expression of cytokines upon
IκBη loss, its overexpression mediated increased luciferase
activity of NF-κB consensus constructs [87]. The obvious
functional similarity to IκBζ suggests redundancy of the
two proteins, but the prolonged carboxy terminal tail is
unique to IκBη (Figure 1). Generation of IκBη-deficient
mice is essential to further determine functional differ-
ences or redundancies between the two proteins.
IκBL
It is still a matter of debate, whether the two reported IκBL
isoforms, α(L) and α(S), belong to the group of IκB pro-
teins, because no REL protein was identified as an inter-
action partner so far. Nevertheless, the protein contains
ankyrin repeats, is localized in the nucleus and suppresses
NF-κB target genes TNFα and IL-6 [88]. Furthermore,
fluorescent microscopy revealed its localisation in nuclear
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IκBζ [73], IκBη [87] as well as IκBNS (unpublished
data). Although both reports strongly indicate the
identification of an additional nuclear IκB protein,
interaction with an NF-κB subunit is a prerequisite to
consider IκBL part of this class.
Conclusions
The BCL-3 subfamily of IκB proteins alters NF-κB activ-
ity in a positive or negative fashion. BCL-3, IκBζ, IκBNS
and IκBη exhibit their function in the nucleus, via asso-
ciation with NF-κB subunits on the DNA. Their main
interaction partners are p50 and p52 within the NF-κB
pathway [32,36,62,78,87]. The observed interaction of
overexpressed human IκBζ with p65 and interaction
studies using GST-IκBNS and in vitro translated REL
proteins suggest, that atypical IκB proteins can also bind
to the other NF-κB subunits [73,78]. However, these in-
teractions might be cell type specific and could depend
on specific stimuli or posttranslational modifications of
IκBs and REL proteins as well. Atypical IκBs exert their
transcriptional function by a magnitude of mechanisms,
whose regulations and interplay are not completely
understood. BCL-3 stabilizes p50 homodimers on the
DNA to silence specific genes because their capacity to
compete with activating p50/p65 heterodimers is in-
creased. On the other hand, it is also possible that BCL-
3 removes p50 homodimers and relocalizes them to the
nucleus in dot-like structures that are associated with
HDAC proteins in order to repress transcription [37]. In
both examples, BCL-3 acts as a factor, which regulates
the maintenance of NF-κB binding to the DNA. Remark-
ably, atypical IκBs can also recruit proteins, which alter
transcription via changes of the chromatin structure.Figure 2 Homology of atypical IκB proteins. Homology tree between th
shown. Numbers indicate evolutionary distance between the different prot
2010; available at www.geneious.com/).BCL-3 interaction with the histone acetyl transferases
p300 and Tip60 [42,43], as well as co-localization of IκBζ
with HDAC4 and HDAC5 was observed using confocal
microscopy [73]. Apparently the interaction with chro-
matin remodeling enzymes is a dynamic process, as
BCL-3 does not exclusively bind to acetyl transferases,
but can also co-localize with HDAC proteins in the nu-
cleus. Further analyses of IκBNS and IκBη are needed to
determine, whether recruitment of histone modifying
enzymes is a mechanism common to all atypical IκB
proteins.
Remarkably, all atypical IκBs are induced via LPS
stimulation (Table 1) [39,61,79,87]. Although the se-
quence similarities of the proteins is high (Figure 2), it
remains unknown, how and if atypical IκB proteins co-
operate or compete with each other during the regula-
tion of common target genes and common interaction
partners like p50. As an example, IκBη and IκBζ were
both shown to force IL-6 production in macrophages, as
loss of these proteins shortened the expression period
and the level of the secreted cytokines [64,87]. These
data suggest a cooperative function. Nevertheless, it is
unknown, whether this depends on direct protein inter-
action between the two IκBs or whether it is mediated
via two different κB binding sites, or via two different di-
mers, which are sequentially exchanged. On the other
hand, IL-6 expression is repressed by IκBNS, since its
loss prolongs the period of cytokine secretion and in-
creases their expression level [79,82]. Thus, IκBNS acts
in an opposite fashion to IκBζ and IκBη. It is highly
likely, that these proteins are sequentially recruited to
the IL-6 locus, to regulate the induction and termination
of cytokine expression. However, comprehensive studies







e atypical IκB proteins IκBζ long, IκBζ short, IκBNS, IκBη and BCL-3 is
eins. Tree was generated by Geneious v5.3 software (Drummond et al.,
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of BCL-3, as the protein is highly upregulated in a var-
iety of cancer cells, suppresses the activity of p53 and
acts in an anti-apoptotic fashion [31-33]. Thus, the ana-
lyses of the BCL-3 expression status might be suitable
for determining the prognosis of tumor progression and
the disease course. It might also represent a suitable
pharmacological target for cancer treatment. Atypical
IκBs are of particular importance for the development of
distinct T helper cell subsets. BCL-3 is an essential me-
diator of TH2 development via GATA-3 upregulation
and IL-4 secretion, without affecting the TH1 subset
[55]. IκBζ-deficient mice are completely protected from
EAE as IκBζ-deficient T cells fail to develop into IL-17
producing TH17 cells [77]. At last, IκBNS drives the de-
velopment of regulatory T cells by binding to regulatory
elements of the Foxp3 locus, whereby IκBNS-deficient
mice display reduced Treg numbers [80]. Thus, there ex-
ists compelling evidence that atypical IκBs are specific
regulators of T helper cell subsets. Therefore, pharmaco-
logical targeting of atypical IκBs might help to develop
therapies to treat diseases, which depend on a certain
T cell subset. As atypical IκBs are involved in a variety
of cellular processes, but the understanding of their mo-
lecular regulation and relationship remains incomplete,
further studies are necessary to uncover their pharma-
cological potential in the future.
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